Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Patent and Trademark Office has issued patent number 7,262,014 to Nventa Biopharmaceuticals covering compositions and methods for inducing or enhancing immune responses to a human papillomavirus antigen with or without the use of an adjuvant.
Subscribe to our email newsletter
This new US patent provides for a method of treating a tumor expressing a human papillomavirus (HPV) antigen through the administration of an effective amount of a composition comprised of an HPV antigen joined or fused to a stress protein. This patent provides additional patent exclusivity for HspE7, the company’s investigational therapeutic vaccine, and future HPV fusions through February 2019.
Gregory McKee, president and CEO of Nventa, said: “The issuance of this patent protecting the use of our HPV CoVal protein fusions to treat HPV-related diseases strengthens our intellectual property portfolio and, we believe, adds further value to our HspE7 program, which is currently in Phase I clinical development.”